ViroCell Biologics (“ViroCell”), founded by the UK’s most prolific academic viral vector manufacturing team, today announces the appointment of Nick Maishman as Chief Operating Officer (“COO”).
ViroCell, an innovation-driven Contract Development and Manufacturing Organisation (“CDMO”), is today addressing the global viral vector supply demand imbalance that constrains the timely manufacture of novel cell and gene therapies. ViroCell focuses exclusively on the design and GMP manufacture of viral vectors and gene modified cells for clinical trials.
ViroCell Biologics, founded by the UK’s most prolific academic viral vector manufacturing team, today announces the appointment of Nick Maishman as Chief Operating Officer (COO).
ViroCell, an innovation-driven Contract Development and Manufacturing Organisation, is today addressing the global viral vector supply-demand imbalance that constrains the timely manufacture of novel cell and gene therapies. ViroCell focuses exclusively on the design and GMP manufacture of viral vectors and gene-modified cells for clinical trials. ViroCell aims to be the global viral vector supplier of choice for the translational development phase of novel cell and gene therapies.
Read MoreViroCell Biologics, a UK contract development and manufacturing organization (CDMO), has announced the appointment of Susan Nichols to its senior management team as chief business officer (CBO).
The firm is seeking to address the global viral vector supply demand imbalance that constrains the timely manufacture of novel cell and gene therapies by focussing on the design and GMP manufacture of viral vectors…
Read MoreViroCell, an innovation-driven Contract Development and Manufacturing Organization (“CDMO”), is addressing the global viral vector supply demand imbalance that constrains the timely manufacture of novel cell and gene therapies. ViroCell focuses exclusively on the design and GMP manufacture of viral vectors and gene modified cells for clinical trials.
ViroCell aims to be the global viral vector supplier of choice for the translational development phase of novel cell and gene therapies.
Read MoreViroCell Biologics, the UK’s first clinical trial-focused viral vector manufacturer, has officially launched.
It aims to be the supplier of choice for viral vectors and gene-modified cells, to academic and corporate clients, for translational cell and gene therapies going into clinical trials.
Read MoreViroCell Biologics,
Read MoreThe global viral vectors and plasmid DNA manufacturing market size was valued at USD 2.87 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 14.71% from 2022 to 2030.
Read MoreViroCell will supply viral vectors and gene modified cells, to academic and corporate clients, for translational cell and gene therapies going into clinical trials.
Read MoreViroCell will supply viral vectors and genetically modified cells to academic and corporate customers for translational cell and gene therapy entering clinical trials.
Read MoreViroCell Biologics – U.K.-based ViroCell launched with the goal to become the supplier of choice for viral vectors and gene-modified cells. Viral vectors are the primary delivery method for many innovative vaccines.
Read MoreViroCell will supply viral vectors and gene modified cells, to academic and corporate clients, for translational cell and gene therapies going into clinical trials.
Read MoreViroCell will supply viral vectors and gene modified cells, to academic and corporate clients, for translational cell and gene therapies going into clinical trials.
Read MoreViroCell Biologics, the first clinical trial focused viral vector manufacturer in the UK, has announced its official launch, with the aim of becoming the ‘supplier of choice’ for viral vectors and gene modified cells.
Read MoreViroCell Biologics, the primary clinical trial focused viral vector manufacturer within the UK, has introduced its official launch, with the intention of turning into the ‘supplier of choice’ for viral vectors and gene modified cells.
Read More